Ordering Guidelines

When should I order?

Order when therapy decisions are unclear or for relapse cases requiring intensive therapy options.

What samples are accepted?

We accept various samples including bone marrow aspirate, with specific logistics for volume and anticoagulants.

How is the report structured?

The report includes an interactive sensitivity heatmap, ranked options, QC flags, and downloadable PDF samples for easy access.

What is chain-of-custody?

Chain-of-custody ensures sample integrity during transport and handling.

How to read the report?

The report provides clear guidance on interpreting results and therapy options.

What integration pathways are available?

Integration pathways include EHR, LIS, and LIMS for seamless data management and reporting.

Innovative Solutions

Advanced therapies for personalized patient care.

Research Collaborations

Partnering for cutting-edge studies.

Clinical Insights

Driving informed treatment decisions.

Technology Integration

Optimizing workflows with innovative tech.

Patient-Centric Approach

Focused on individual patient outcomes.

→

→

→

→

4. LEAD THE CHANGE

We help clinicians, patients, and industry teams explore therapy options using ex vivo evidence: safely, transparently, and with rigorous governance.

For Haematologists

Run an investigator-led pilot inside routine workflows. We supply kits, SOPs and logistics; patient-derived cells are tested in our engineered bone-marrow avatars. You receive a concise pilot report designed to support tumor-board discussion (mock preview available). Target TAT from sample receipt: ≤72h. Investigational use only (not CE-IVD).

For Patients & Caretakers

We are now for investigational use only. However, you can partner with us via your Haematology team: join our Patient Advisory Circle, give usability feedback, or participate in ethics-approved pilots when available. Always optional, privacy-first, withdrawable anytime. Your consented input helps us shape tomorrows' fully personalised, patient-shared decision-making.

Use ex vivo patient biology in haem-onc to triage trial candidates, prioritise combos, and generate responder-enrichment hypotheses. Define cohorts, endpoints, QC, and data packages; align timelines in a study-design session—leveraging NAMs-aligned, near-human platforms supporting FDA Modernization Act 2.0 for drug discovery/validation.

For Pharmaceutical partners

3. HOW IT WORKS